[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Endeavor Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":591},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,72,97,118,143,173,205,231,265,293,322,346,368,393,412,433,454,476,504,524,551,571],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053237","icu-connect-study-comparing-emg-in-healthy-volunteers-and-icu-patients-100053237",false,"NCT07699562","ICU CONNECT: Study Comparing EMG in Healthy Volunteers and ICU Patients.","ICU CONNECT Trial: A MultIcenter Comparison Cohort Trial EvalUating the Correlation Between nOn-iNvasive EMG and iNvasive EMG in Healthy Volunteers and Critically Ill PaTients","ICU CONNECT","Inclusion Criteria:\n\n* Cohort 1: Healthy volunteers\n\nInclusion criteria:\n\n* Subjects must be \\> 18 years old and \\\u003C 90 years old.\n* Subjects must consent to participate. Cohort 2: Non-intubated critically ill patients\n\nInclusion criteria:\n\n* Subjects may be male or female.\n* Subjects must be \\> 18 years old and \\\u003C 90 years old.\n* Subjects must have a POA or next of kin who is able to consent (for those in the ICU and who are unable to consent themselves).\n\nCohort 3: Intubated critically ill patients\n\nInclusion criteria:\n\n* Subjects may be male or female.\n* Subjects must be \\> 18 years old and \\\u003C 90 years old.\n* Subjects must have a POA or next of kin who is able to consent (for those in the ICU and who are unable to consent themselves).\n* For the Subjects in the ICU that are intubated, they must be planned to be intubated for at least 24 hours.\n* Subjects must be intubated for no longer than ≥ 72 hours before enrollment.\n\nExclusion Criteria:\n\n* Cohort 1: Healthy volunteers\n\nExclusion criteria:\n\n* Subjects with previous paralysis or neuromuscular disease.\n* Subjects with spinal cord or brain injuries that impact motor function.\n* Subjects with an allergy to clinical adhesive or hydrogel. Cohort 2: Non-intubated critically ill patients\n\nExclusion criteria:\n\n* Subjects with previous paralysis or neuromuscular diseases.\n* Subjects with previous peripheral nerve injuries to the tested limbs.\n* Subjects with spinal cord or brain injuries (including stroke) that impact motor function.\n* Subjects without a POA or next of kin for those patients that are unable to consent themselves.\n* Subjects with an allergy to clinical adhesive or hydrogel. Cohort 3: Intubated critically ill patients\n\nExclusion criteria:\n\n* Subjects with previous paralysis or neuromuscular disease\n* Subjects with previous peripheral nerve injuries to the tested limbs.\n* Subjects with spinal cord or brain injuries that impact motor function.\n* Subjects without a POA or next of kin for those patients that are in the intubated arm.\n* Subjects with intubations expected to last less than 24 hours.\n* Subjects who have already been intubated for \\> 72 hours.\n* Subjects with an allergy to clinical adhesive or hydrogel.",true,"ALL","18 Years","90 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is testing whether a non-invasive nerve monitoring device (TetraGraph) can accurately detect early signs of ICU-acquired weakness by comparing readings from the device with standard nerve conduction\u002FEMG tests done by a specialist to see if they match. They will focus on muscle response signals in the hand and leg over about 10 days in three groups: healthy volunteers, ICU patients who are not on ventilators, and ICU patients who are on ventilators.",[29],"ICU Acquired Weakness","RECRUITING","2026-07-07",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":23},"2026-06",{"date":38,"type":23},"2027-09",{"name":40,"class":41},"Endeavor Health","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100624124","phase-2-zinc-supplementation-with-botulinum-toxin-for-overactive-bladder-100624124","NCT07405554","Zinc Supplementation With Botulinum Toxin for Overactive Bladder","Effect of Zinc Supplementation on Botulinum Toxin for Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Non-pregnant adult female at least 21 years old, with no plans to become pregnant during the course of the trial) and if of child-bearing potential, with a negative pregnancy test, and if sexually active, must be using medically acceptable contraception.\n* ≥ 6 urgency urinary incontinence episodes on a 3-day baseline bladder diary, with these urge incontinence episodes representing greater than 50% of the total incontinent episodes recorded.\n* Willing and able to complete all study related items and interviews.\n* Refractory urgency urinary incontinence: defined as persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, supervised physical therapy)\n* Persistent symptoms despite the use of a minimum of two anticholinergics, or unable to tolerate medication due to side effects, or has a contraindication to taking anticholinergic\u002FBeta 3 agonist medication.\n* Currently not on an anticholinergic or antimuscarinic\u002FBeta 3 agonist medication (e.g. oxybutynin, tolterodine, darifenacin, trospium chloride, solifenacin-succinate, fesoterodine and\u002For mirabegron) or be willing to stop medication for 3 weeks prior to completing baseline bladder diary and expected to remain off medications through duration of study.\n* Demonstrates ability (or have caregiver demonstrate ability) to perform clean intermittent self-catheterization.\n* Grossly neurologically normal on exam and no gross systemic neurologic conditions believed to affect urinary function.\n\nExclusion Criteria:\n\n* Neurologic diseases such as multiple sclerosis, Parkinson Disease, CVA within 6 months prior to enrollment, myasthenia gravis, Charcot-Marie-Tooth disease, clinically significant peripheral neuropathy, and complete spinal cord injury.\n* Untreated urinary tract infection (UTI).\n* Any prior use of either study therapy for treatment of urinary urge incontinence (Botox A® or Interstim®).\n* PVR \\>150 ml on 2 occasions within 6 months prior to enrollment (If the PVR value was obtained by ultrasound and was ≥150 ml, the PVR will be confirmed by catheterization which will be the gold standard).\n* Current or prior bladder malignancy.\n* Surgically altered detrusor muscle, such as augmentation cystoplasty.\n* Subjects taking aminoglycosides.\n* Currently pregnant or lactating.\n* Allergy to lidocaine or bupivacaine.\n* Prior pelvic radiation.\n* Uninvestigated hematuria.","FEMALE","21 Years","100 Years",{"count":54,"type":23},72,[56],"PHASE2","This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching placebo for five days prior to intradetrusor botulinum toxin injection. Participants will be followed for six months after treatment to assess need for repeat botulinum toxin injection, urinary symptoms, and patient-reported outcomes related to overactive bladder.",[59],"Overactive Bladder (OAB)",[61,62,63],"overactive bladder","botulinum toxin","zinc","2026-07-01",{"date":66,"type":34},"2026-07-02",{"date":68,"type":34},"2026-02-26",{"date":70,"type":23},"2026-12",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":24,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100641542","phase-4-fasenra-an-asthma-study-100641542","NCT07654842","Fasenra: An Asthma Study","Fasenra Demonstrates Durability Over the Full 8-week Treatment Period","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.\n2. At least 18 years of age at the time of signing the informed consent at Visit 1.\n3. Documented asthma diagnosis ≥12 months prior to Visit 1. This may be documented by physician-diagnosis or by documented pharmacy records.\n4. Treated with a daily ICS-containing maintenance inhaler for asthma at a stable dose for ≥3 months prior to Visit 1. This inhaler may contain ICS alone, or in combination with a LABA or LABA-LAMA. The prescribed inhaler must be compatible with a study-provided EMM (see Appendix A).\n5. Prescribed a SABA-containing reliever inhaler, AND willing to use study-provided ICS-SABA reliever with EMM provided by the study.\n6. Prescribed benralizumab for severe eosinophilic asthma for ≥6 months AND has had ≥4 benralizumab doses (3 loading doses + at least 1 8-week dosing interval).\n\nExclusion Criteria:\n\n1. Current smoker (including tobacco, vaping, and marijuana). Former smokers must have stopped ≥6 months prior to Visit 1.\n2. Has a known, preexisting, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, hematological, or any other system abnormalities that are uncontrolled with standard treatment, which, in the investigator's opinion, would compromise the participant's safety, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence.\n3. History of use of any biologic therapy for asthma (other than benralizumab) within 5 half-lives or 5 months, whichever is longer, before Visit 1.\n4. A severe asthma exacerbation within 4 weeks of Visit 1. For this study, a severe asthma exacerbation is defined as an episode of worsening asthma symptoms that result in at least one of the following:\n\n   * Use of systemic corticosteroids for at least 3 consecutive days (or a single depo-injectable dose of corticosteroids)\n   * An inpatient hospitalization (defined as admission to an inpatient facility and\u002For evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma\n   * An emergency department visit (defined as evaluation and treatment for \\\u003C24 hours in an emergency department or urgent care) due to asthma that required systemic corticosteroids (as per above)\n5. Current enrollment in an asthma-related clinical trial.\n6. Any known history of adverse reactions to budesonide-albuterol.",{"count":80,"type":23},40,[82],"PHASE4","The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.\n\nParticipants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.",[85,86,87,88],"Eosinophilic Asthma","Severe Asthma","Severe Eosinophilic Asthma","Asthma","NOT_YET_RECRUITING","2026-06-12",{"date":92,"type":34},"2026-06-17",{"date":64,"type":23},{"date":95,"type":23},"2028-01-01",{"name":40,"class":41},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100642649","phase-4-aprepitant-to-improve-same-day-discharge-for-tka-100642649","NCT07639723","Aprepitant to Improve Same Day Discharge for TKA","Preoperative Aprepitant to Improve Same-Day Discharge After Total Knee Arthroplasty: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Receiving primary, unilateral elective TKA with or without abductor canal block\n* Asa I-III\n* Age 18-90\n* Ability to receive ondansetron and dexamethasone\n* Ability to consent and complete surveys\n* English or Spanish speaking\n* Receiving regional anesthesia (epidural or spinal) for surgery\n\nExclusion Criteria:\n\n* Allergy to any of the anti-emetics being administered\n* Current treatment of pimozide\n* Emergent surgery\n* Revision\u002F multiple revisions of TKA\n* Clinical suspicion of possible bowel obstruction\n* Need for general anesthesia\n* Pregnant\u002Fbreast feeding\n* AST\\> 2.5 x the upper limit of normal or ALT\\> 2.5 x upper limit of normal, bilirubin\\> 1.5x upper limit of normal\n* Need for opioid or benzodiazepine antagonists\n* Not planned for same day discharge\n* Enrollment in a different drug trial for TKA\n* Unable to consent in English or Spanish",{"count":105,"type":23},350,[82],"The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.",[109],"PONV","2026-06-06",{"date":112,"type":34},"2026-06-10",{"date":114,"type":23},"2026-07",{"date":116,"type":23},"2027-08",{"name":40,"class":41},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":50,"minAge":19,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":42},"100540220","beyond-mars-magnetic-resonance-study-a-novel-assessment-of-placental-perfusion-during-pregnancy-100540220","NCT06314009","Beyond MARS: Magnetic Resonance Study: A Novel Assessment of Placental Perfusion During Pregnancy","Inclusion Criteria:\n\n* Singleton pregnancy, less than 24 weeks gestation\n* Pre-pregnancy BMI between 18.5 - 24.9kg\u002Fm2 or ≥30kg\u002Fm2\n\nExclusion Criteria:\n\n* Asthma on controller medication\n* Autoimmune Conditions\n* Chronic Hypertension\n* Claustrophobia\n* Congenital Anomaly\n* Pregestational Diabetes\n* History of Bariatric Surgery\n* HIV\n* Ineligible for MRI (incompatible implanted medical device)\n* Multifetal Gestation\n* Smoking during pregnancy","60 Years",{"count":126,"type":23},30,"OBSERVATIONAL","The purpose of this study is to evaluate the flow of oxygen and blood necessary for nutrient transfer across the placenta during the second and third trimesters in pregnancy in women who are obese before pregnancy compared to women who have an average weight before pregnancy.\n\nThis study will evaluate blood flow across the placenta by functional Magnetic Resonance Imaging (fMRI). The investigators hypothesize that there will be differences in placental oxygenation and blood flow among women with obesity as compared to those with normal weight.\n\nParticipants will be asked to complete:\n\n* MRI in the second trimester (20-24 weeks)\n* MRI in the third trimester (30-34 weeks)",[130],"Pregnancy",[132,133,134,135],"Placenta","MRI","BMI","Weight","2026-03-13",{"date":138,"type":34},"2026-03-16",{"date":140,"type":34},"2024-05-09",{"date":70,"type":23},{"name":40,"class":41},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":156,"studyType":127,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100461957","performance-of-inherited-risk-assessment-for-predicting-prostate-cancer-from-prostate-biopsy-100461957","NCT05295407","Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy","Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)","GenBx","Inclusion Criteria:\n\n* Consecutive patients undergoing prostate biopsy for detection of prostate cancer\n* Aged 40 to 69 years\n* Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)\n* PSA between 2.5-10 ng\u002FmL\n\nExclusion Criteria:\n\n* Previous diagnosis of prostate cancer.\n* Ethnicity outside the inclusion criterion (including mixed ethnicity).\n* Any prior PSA test result outside the range of inclusion criterion.","MALE","40 Years","69 Years",{"count":155,"type":23},1000,"2 Months","Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment",[159],"Prostate Cancer",[161,162,163,164],"Prostate biopsy","prostate cancer","inherited risk assessment","PSA","2026-02-24",{"date":167,"type":34},"2026-02-27",{"date":169,"type":34},"2021-12-13",{"date":171,"type":23},"2027-12-13",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":42},"100579754","improving-safety-patient-experience-and-equity-through-shared-decision-making-huddles-in-labor-100579754","NCT06828406","Improving Safety, Patient Experience and Equity Through Shared Decision-making Huddles in Labor","Improving Safety, Patient Experience, and Equity Through Shared Decision-making Huddles in Labor (I'M SPEAKING)","I'M SPEAKING","Inclusion Criteria:\n\n* Age 18 or older\n* English or Spanish speaking\n* Gave birth to a live-born infant after laboring\n\nExclusion Criteria:\n\n* Speaks a language other than English or Spanish\n* Under the age of 18\n* Gave birth to a nonliving infant\n* Cesarean delivery without labor",{"count":182,"type":23},2200,[26],"To evaluate the effectiveness of an existing quality improvement (QI) training program known as TeamBirth, using a randomized stepped-wedge hybrid type II study design, to (a) decrease nulliparous term singleton vertex (NTSV) cesarean birth (CB) across all birthing people, and specifically for Black birthing people, and (b) increase shared decision-making (SDM), (c) improve patient experience of respectful care. TeamBirth uses a train-the-trainer model to implement patient-participatory shared decision-making on Labor and Delivery (L\\&D) units, with the goal of decreasing unwanted and unnecessary interventions and improving patient experiences and outcomes for labor and birth.",[186],"Perinatal Decision Making",[188,189,190,191,192,193,194,195,196],"Shared Decision Making","Quality Improvement","Cesarean Birth","Labor and Delivery","Nulliparous Term Singleton Vertex","Illinois Perinatal Quality Collaborative","Promoting Vaginal Birth","Birth Equity","Severe Maternal Morbidity","2026-02-01",{"date":199,"type":34},"2026-02-03",{"date":201,"type":34},"2025-04-29",{"date":203,"type":23},"2029-07",{"name":40,"class":41},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":212,"targetDuration":4,"studyType":24,"phases":214,"briefSummary":215,"conditions":216,"keywords":221,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":42},"100601002","autonomic-neural-blockade-in-bariatric-surgery-100601002","NCT07104825","Autonomic Neural Blockade in Bariatric Surgery","Autonomic Neural Blockade During Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial Evaluating Pain and Nausea After Bariatric Surgery","Inclusion Criteria:\n\n* Individuals able and willing to consent and participate in all study activities\n* Adults, ages 18-90\n* All patients with severe obesity undergoing laparoscopic\u002Frobotic gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients taking opiates chronically\n* Patients allergic to study medications\n* Patients with any prior adverse reaction to ingredients included in the block\n* Adults unable to consent\n* Pregnant women\n* Prisoners",{"count":213,"type":23},200,[26],"The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain\u002Fnausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.",[217,218,219,220],"Bariatric Surgery Candidate","Pain, Postoperative","Nausea and Vomiting, Postoperative","Opioid Use",[222],"Autonomic, blockade, bariatric surgery","2026-01-27",{"date":225,"type":34},"2026-01-29",{"date":227,"type":23},"2026-03",{"date":229,"type":23},"2027-12",{"name":40,"class":41},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":24,"phases":240,"briefSummary":241,"conditions":242,"keywords":247,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":42},"100374281","phase-2-ivig-in-the-treatment-of-autoimmune-small-fiber-neuropathy-with-ts-hds-fgfr-3-or-plexin-d1-antibodies-100374281","NCT04153422","IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies","Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial","Inclusion Criteria:\n\n1. Patients ≥ age 18\n2. Patient with clinical and biopsy evidence of pure small fiber neuropathy (with or without dysautonomia) as evidenced by reduced IENFD on skin biopsy using PGP 9.5 as the immunostain. Biopsy must have been performed within 12 months of study enrollment. If biopsies were not done at CRL, they will be repeated and done at 3 sites (upper and lower thigh, lower calf), to have consistent and equivalent biopsy data with the follow up biopsy done after 6 mos of treatment\n3. Patients must have elevated and\u002For abnormal titers of autoantibodies to TS-HDS-IgM, FGFR3-IgG, or Plexin-D1 measured by the Washington University Neuromuscular Laboratory (St Louis) within 12 mos of enrollment\n4. Patients must have a baseline pain score on a visual analogue scale (VAS) of Greater or equal to 4\u002F10\n5. Patients must have a baseline Utah Early Neuropathy Scale (UENS) score of Greater or equal to 4\u002F10\n6. Small Fiber Neuropathy Screening List (SFNSL) score of 11\u002F84 or greater\n7. Non-pregnant, non-lactating female. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during treatment\n\nExclusion Criteria:\n\n1. Any other known cause for small fiber neuropathy other than the presence of the elevated titers of TS-HDS-IgM, FGFR3-IgG, or Plexin-D1 autoantibodies\n2. Patients with generalized, severe musculoskeletal conditions other than SFN that prevent a sufficient assessment of the patient by the physician\n3. Electromyography\u002Fnerve conduction study (EMG\u002FNCS) evidence of large fiber polyneuropathy, to be confirmed by study PI\n4. Underlying severe heart, kidney, liver disease, or HIV infection, (Note: If there is no previous HIV test result documented within the last 5 years, a test may be performed in order to confirm eligibility)\n5. Patients with a history of deep vein thrombosis within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or deep vein thrombosis\n6. Known significant IgA deficiency with antibodies to IgA\n7. History of hypersensitivity, anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of IVIG 10%\n8. Known blood hyperviscosity, or other hypercoagulable states\n9. Use of IgG products within six months prior to enrollment\n10. Patients with a history of drug or alcohol abuse within the past five years prior to enrollment\n11. Patients unable to understand or unwilling or unable to comply with the study protocol",{"count":239,"type":23},20,[56],"This study will enroll patients with small fiber neuropathy (SFN). The study will look at an intravenous immunoglobulin (IVIG) called Panzyga. Panzyga is approved by the FDA as a therapy for Primary humoral immunodeficiency (PI) in patients 2 years of age and older; Chronic immune thrombocytopenia (ITP) in adults and Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. It has not been approved by the FDA for use in SFN.\n\nThere is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies in great numbers in SFN patients. The primary outcome is quantified improvement in intraepidermal nerve fiber density (IENFD) on repeat skin punch biopsy after 6 months of IVIG treatment.",[243,244,245,246],"Small Fiber Neuropathy","Autoimmune Small Fiber Neuropathy","Inflammatory Polyneuropathy","Immune-Mediated Neuropathy",[243,248,249,250,251,252,253,254,255,256],"Neuropathy","Intravenous Immunoglobulin","IVIG","TS-HDS antibody","FGFR-3 antibody","FGFR3 antibody","Immune mediated small fiber neuropathy","Panzyga","Plexin D1 antibody","2026-01-07",{"date":259,"type":34},"2026-01-09",{"date":261,"type":34},"2023-12-15",{"date":263,"type":23},"2028-02-28",{"name":40,"class":41},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":24,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100473193","furthering-equity-through-infant-feeding-education-and-support-100473193","NCT05441709","Furthering Equity Through Infant Feeding EDucation and Support","Clinically Integrated Breastfeeding Peer Counseling to Promote Breastfeeding Equity","FEEDS","Inclusion Criteria:\n\n* 12 and 24 weeks gestation\n* English or Spanish speaking\n* Planning to parent their infant\n* Planning to deliver at SH, HPH or UCM\n* No prior exposure to ci-BPC\n\nExclusion Criteria:\n\n* considering pregnancy termination or adoption\n* Prior exposure to ci-BPC","45 Years",{"count":275,"type":23},990,[26],"The purpose of this study is to identify whether adding clinically integrated breastfeeding peer counseling (ci-BPC) to standard lactation care is associated with a reduction in disparities in breastfeeding intensity and duration for Black and Hispanic\u002FLatine families.",[279],"Breastfeeding",[279,281,282,283],"Peer Counseling","Lay health worker","Infant Feeding","2025-12-06",{"date":286,"type":34},"2025-12-09",{"date":288,"type":34},"2022-11-08",{"date":290,"type":23},"2026-12-31",{"name":40,"class":41},4,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":50,"minAge":19,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":24,"phases":304,"briefSummary":305,"conditions":306,"keywords":310,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":42},"100582331","phase-4-nsaid-use-for-treating-dysmenorrhea-and-preventing-chronic-pelvic-pain-nsaid-heal-100582331","NCT06861920","NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)","Targeting Interindividual Variability in NSAID Responses to Mitigate Chronic Pelvic Pain Risk in Dysmenorrhea (NSAID HEAL)","NSAIDHEAL","Inclusion Criteria:\n\n* aged 18-35\n* individuals who menstruate, with painful periods\n* regular menstrual cycles (every 22-35 days)\n\nExclusion Criteria:\n\n* presence of active pelvic or abdominal malignancies (primary or metastatic)\n* conditions associated with the absence of regular menses such as polycystic ovarian syndrome, pregnancy, or any current use of continuous hormonal medication or contraceptive\n* unable to read or comprehend the informed consent in English\n* presence of other diagnosed chronic back or pelvic pain conditions (including chronic back pain, fibromyalgia, bladder pain syndrome, irritable bowel syndrome, vulvar pain syndrome, and endometriosis-associated pelvic pain)\n* having another diagnosed\u002Fsymptomatic chronic pain condition besides migraines with an average pain score \\>3\u002F10 in the last month when not consuming pain relievers, or that requires daily treatment with opioids (ex. hydrocodone, oxycodone, codeine, morphine, hydromorphone, tapentadol, tramadol) or neuromodulators (also known sometimes as antidepressants \\[ex. amitriptyline, nortriptyline, imipramine, duloxetine, milnacipran, venlafaxine\\] or antiseizure medications \\[ex. topiramate, gabapentin, pregabalin, carbamazepine, lamotrigine\\])\n* current or past history of stomach ulcers\n* current or past history of gastrointestinal (GI) bleeding\n* diagnosis of peptic ulcer disease\n* current or past history of renal disorders\n* current or past history of adrenal dysfunction\n* diagnosis of liver disorders\n* diagnosis of chronic acid reflex (i.e. GERD)\n* Diagnosis of Crohn's disease or ulcerative colitis\n* Coagulopathy\n* Prolactinoma\n* Von Willebrand disease\n* Platelet disorders\n* High blood pressure that is difficult to manage\n* gastrointestinal conditions or surgeries that affect naproxen absorption\n* bleeding disorders\n* heart failure\n* a history of stroke\n* a history of heart attack\n* active genitourinary or sexually transmitted infection\n* allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or their ingredients\n* individuals who take the following medications: anticoagulants (i.e. warfarin), lithium, diuretics, antacids, angiotensin-converting enzyme (ACE) inhibitors, methotrexate, cholestyramine, or probenecids.\n* Unmanaged diabetes (i.e. Fasting Blood Glucose: ≥ 126 mg\u002FdL (≥ 7.0 mmol\u002FL), Non-Fasting\u002FRandom Blood Glucose: ≥ 200 mg\u002FdL (≥ 11.1 mmol\u002FL), Hemoglobin A1c (HbA1c): ≥ 6.5%)\n* Uncontrolled thyroid function (i.e. Hypothyroidism (Underactive Thyroid): Thyroid-Stimulating Hormone (TSH): \\> 4.5 mIU\u002FL (mild) or \\> 10 mIU\u002FL (severe) Free T4: Below the lower end of the reference range (usually \\\u003C 0.9 ng\u002FdL)\n* Hyperthyroidism (overactive thyroid) (i.e. TSH: \\\u003C 0.4 mIU\u002FL (Suppressed or undetectable), Free T4: Above the upper end of the reference range (usually \\> 2.0 ng\u002FdL)\n* Liver dysfunction (i.e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin (unless known diagnosis of Gilbert's syndrome) ≥ 1.5 times the upper limit of the reference range)\n* Kidney dysfunction (i.e. Serum creatinine \\> 1.1 mg\u002FdL.)","35 Years",{"count":303,"type":23},600,[82],"The goal of this clinical trial is to learn if NSAIDs (i.e. naproxen sodium) can treat menstrual pain and prevent the development of chronic pelvic pain in menstruating adults with painful periods. The main questions it aims to answer are:\n\n* Can non-menstrual pelvic pain reduction be predicted by menstrual pain response to NSAIDs?\n* Will participants with the largest reductions in multi-site sensitivity following NSAID therapy have the largest reductions in non-menstrual pelvic pain?\n\nResearchers will compare naproxen sodium to a placebo (a look-alike substance that contains no drug) to see if naproxen sodium works to treat painful periods.\n\nParticipants will:\n\n* Take naproxen sodium or placebo during several days of their menstrual period every month for 1 year.\n* Complete computer questionnaires and tests from home every 3 months.\n* Complete at-home urine tests to measure hormones every few days for 1-year.\n* Use a pin-prick to collect a small spot of blood, and use a pad or tampon to collect a sample of menstrual blood, and bring it to the research site twice over a 1-year period.\n* Come to the research site twice over a 1-year period to complete sensory assessments and undergo a blood draw.\n\nThe major goal of the study is to develop a multivariable statistical model (see https:\u002F\u002Fgrants.nih.gov\u002Fgrants\u002Fguide\u002Frfa-files\u002FRFA-NS-24-021.html ) describing the factors that effectiveness of pain medication and risk for chronic pain",[307,308,309],"Dysmenorrhea","Chronic Pelvic Pain","Pelvic Pain",[311,312,308,309,313],"Painful Periods","NSAIDs","Periods","2025-08-04",{"date":316,"type":34},"2025-08-07",{"date":318,"type":34},"2025-04-07",{"date":320,"type":23},"2030-07",{"name":40,"class":41},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":24,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":42},"100521806","phase-4-non-inferiority-trial-investigating-surfactants-administered-via-mist-100521806","NCT06074380","Non Inferiority Trial Investigating Surfactants Administered Via MIST","Niftisurf","Inclusion Criteria:\n\n* Preterm infants 28-35 6\u002F7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome confirmed by a chest x-ray on nasal continuous positive airway pressure (NCPAP) and FiO2 ≥0.30\n\nExclusion Criteria:\n\n* Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.\n* Infants who require emergent intubation will not be enrolled in the interventions.","48 Hours",{"count":331,"type":23},262,[82],"RESEARCH DESIGN Multicenter, randomized, controlled trial. RECRUITMENT Entry criteria Preterm infants 28-35 6\u002F7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome. Infants who are on NCPAP and FiO2 ≥0.30 will randomized to curosurf or infasurf via MIST.\n\nExclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.\n\nBabies who require emergent intubation will not be enrolled in the interventions.\n\nParental Consent will be obtained prior to randomization.",[335],"Respiratory Distress Syndrome",[337,338,339],"Pulmonary Surfactant","CPAP","Neonate",{"date":316,"type":34},{"date":342,"type":34},"2024-01-01",{"date":344,"type":23},"2027-12-01",{"name":40,"class":41},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":367,"locationsCount":42},"100516670","phase-4-prophylactic-minimally-invasive-surfactant-evaluation-100516670","NCT06007547","Prophylactic Minimally Invasive Surfactant Evaluation","PreProMISe","Inclusion Criteria:\n\n* Gestational age \\\u003C30 weeks\n* Antenatal consent from Parent\n\nExclusion Criteria:\n\n* Congenital anomalies\n* Alternate cause of respiratory distress","15 Minutes",{"count":213,"type":23},[82],"The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?",[358,359],"Respiratory Distress Syndrome, Newborn","Premature Birth",[335,361,362],"surfactant","Minimally invasive Surfactant Therapy",{"date":316,"type":34},{"date":342,"type":34},{"date":366,"type":23},"2027-07-31",{"name":40,"class":41},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":124,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":42},"100516450","phase-2-using-placental-pathology-to-prevent-recurrent-adverse-pregnancy-outcomes-a-pilot-project-100516450","NCT06004674","Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project","Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project (UPPPP Trial)","Eligibility Criteria:\n\nInclusion (must meet all three criteria):\n\n1. Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \\\u003C 37 weeks), SGA infant (defined as birthweight \\\u003C 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician\n2. Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist\n3. Current singleton pregnancy at \\\u003C16 6\u002F7 weeks gestational age.\n\nExclusion Criteria:\n\n1. Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin)\n2. Known major fetal anomaly\n3. Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \\\u003C100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol\n4. Chronic kidney disease with eGFR\\\u003C 60\n5. Known chronic liver disease with baseline AST\u002FALT \\> 3 x upper limit of normal\n6. Subjects with mechanical prosthetic heart valves",{"count":239,"type":23},[56],"The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events.\n\nThe main questions it aims to answer are:\n\n* Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM).\n* If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.",[379],"Adverse Pregnancy Outcome",[381,382,383,384,385],"miscarriage","preeclampsia","preterm delivery","stillbirth","Low birth weight","2025-07-29",{"date":388,"type":34},"2025-07-31",{"date":390,"type":34},"2023-12-26",{"date":227,"type":23},{"name":40,"class":41},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":124,"enrollmentInfo":399,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":42},"100517816","prenatal-sonographic-prediction-of-placental-histology-and-function-100517816","NCT06022458","Prenatal Sonographic Prediction of Placental Histology and Function","Retrospective Phase\n\nInclusion criteria:\n\n* Patients with delivery in NorthShore University HealthSystem,\n* Ultrasound available within 4 weeks of delivery with adequate placental images\n* Placental pathology available\n\nExclusion criteria:\n\n* Multiple gestation\n\nProspective Phase Inclusion criteria\n\n* Exposed: Patients with singleton gestation with fetal growth restriction at 20-28 weeks with a plan to deliver at NorthShore Highland Park Hospital Evanston Hospital. Patients must have a first-trimester ultrasound (\\\u003C14 weeks) to confirm pregnancy dating available in the electronic medical record.\n* Unexposed: Patients who present for routine ultrasound evaluation at 36-38 weeks with normal fetal growth with a plan to deliver at NorthShore Highland Park Hospital or NorthShore Evanston Hospital.\n\nExclusion criteria:\n\n* Exposed: Multiple gestation, major fetal anomaly\n* Unexposed: Multiple gestation, history of chronic hypertension, gestational or pregestational diabetes, major fetal anomaly antiphospholipid syndrome, known thrombophilia",{"count":400,"type":23},320,"The purpose of this two-phase observational study is to investigate the use of ultrasonography to predict placental pathology at the time of delivery.",[403],"Pregnancy Complications",[405,406],"placenta pathology","adverse pregnancy outcomes",{"date":388,"type":34},{"date":409,"type":34},"2024-05-28",{"date":227,"type":23},{"name":40,"class":41},{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":17,"sex":50,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":42},"100585105","postpartum-ultrasound-evaluation-to-assess-risk-of-hemorrhage-100585105","NCT06898034","Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage","Inclusion Criteria:\n\n* Currently pregnant and planning to deliver at Endeavor Health \\>37 weeks gestational age\n* English speaking\n* Labor \\\u003C6cm dilated at time of consent without epidural\n* Labor \\\u003C8cm dilated at time of consent with epidural\n\nExclusion Criteria:\n\n* Preterm delivery\n* Non-English speaking\n* Any conditions that impairs potential participants decision making","17 Years",{"count":420,"type":23},1725,"Up to 5% of patients in the United States have a postpartum hemorrhage. \"Postpartum hemorrhage\" means excessive bleeding after delivery. The majority of these bleeds occur immediately with delivery.\n\nThe current study focuses on hemorrhages that occur in the \"medium-term\" (1.5-24 hours after delivery). Investigators are examining whether ultrasound exams performed at the beginning of this period 1.5 to 2 hours after birth can identify markers that predict a medium-term bleed. Data collected for this study will include medical and obstetrical history, details about the course and outcomes of patients' labor and delivery, and particulars about postpartum bleeding. This information will be collected through the end of the patients' delivery admission and will allow correlation with the results of the ultrasound exam. If patients are re-admitted to the hospital after the delivery discharge, investigators may also collect relevant information about those admissions up to 6 weeks postpartum.\n\nAll patients after term delivery (≥ 37 weeks' gestation) will be eligible to participate. Patients will be approached to provide consent for participation as early as feasible during a prenatal visit (≥ 36 weeks' gestation) or during the delivery admission. No subjects will be consented while in significant pain, \\>6cm dilated without an epidural, or \\>8cm dilatated with an epidural.",[423,424],"Pregnancy Related","Post Partum Hemorrhage","2025-03-20",{"date":427,"type":34},"2025-03-27",{"date":429,"type":34},"2025-03-10",{"date":431,"type":23},"2027-03",{"name":40,"class":41},{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":151,"minAge":273,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":42},"100520923","phase-2-effects-of-tnf-blockade-on-human-bphluts-100520923","NCT06062875","Effects of TNF Blockade on Human BPH\u002FLUTS","Inclusion Criteria:\n\n* Male sex\n* Age 45-80 years\n* Diagnosed by physician with BPH\n* Prostate volume ≥ 60mL\n* IPSS ≥ 8\n* Able and willing to complete questionnaires\n* Able and willing to provide informed consent\n* Able to read, write, and speak in English\n* No prior treatment with TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab)\n* No plans to move from study area in the next 6 months\n\nDeferral Criteria:\n\n* Microscopic hematuria without appropriate workup per AUA\u002FSociety of Urodynamics, Female Pelvic Medicine \\& Urogenital Reconstruction (SUFU) Guidelines\n* Positive urine culture\n\nExclusion Criteria:\n\n* Female sex or intersex\n* Age \\\u003C 45 or \\> 80 years\n* Being a prisoner or detainee\n* Urinary retention with need for catheterization\n* Gross hematuria\n* Contraindication to treatment with adalimumab (e.g., presence of sepsis or active infection, active tuberculosis, Hepatitis B infection, invasive fungal infection, lymphoma, leukemia or other active malignancy, congestive heart failure, significant hematologic abnormality, allergy to adalimumab or its components, anti-drug antibodies, congestive heart failure)\n* Diagnosis of autoimmune disease (rheumatoid arthritis, plaque psoriasis, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, spondyloarthritis)\n* Interstitial cystitis\n* Pelvic or endoscopic genitourinary surgery within the preceding 6 months (not including diagnostic cystoscopy)\n* History of lower urinary tract or pelvic malignancy including prostate cancer; history of pelvic radiation therapy\n* Ongoing symptomatic urethral stricture\n* Current chemotherapy or other cancer therapy\n* Severe neurological or psychiatric disorder that would prevent study participation (e.g., bipolar disorder, psychotic disorder, Alzheimer's Disease)\n* Current moderate or severe substance use disorder","80 Years",{"count":441,"type":23},70,[56],"Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH\u002FLUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.",[445],"Benign Prostatic Hyperplasia (BPH)","2024-11-18",{"date":448,"type":34},"2024-11-21",{"date":450,"type":34},"2024-01-24",{"date":452,"type":23},"2028-06-01",{"name":40,"class":41},{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":42},"100510031","fasting-mimicking-diet-fmd-in-conjunction-with-chemotherapy-in-advanced-ovarian-cancer-100510031","NCT05921149","Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer","A Randomized Controlled Study of a Fasting Mimicking Diet (FMD) in Conjunction With Combination Carboplatin and Paclitaxel in the Treatment of Patients With Advanced or Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. All patients with advanced ovarian, fallopian tube and primary peritoneal carcinomas deemed appropriate candidates for neoadjuvant chemotherapy and patients with recurrent, platinum-sensitive disease (as defined by an interval of at least 6 months following completion of last platinum-based chemotherapy prior to disease relapse or progression)\n3. ECOG Performance Status of 0, 1 or 2.\n4. Adequate bone marrow reserve (absolute neutrophil count (ANC) ≥1.5 x 109\u002FL and platelet count ≥100 x 109\u002FL).\n5. Adequate renal function defined as creatinine ≤1.5 x laboratory upper limit of normal (ULN).\n6. Adequate hepatic function defined as:\n\n   Bilirubin ≤1.5 x ULN ALT and AST ≤3 x ULN\n7. BMI ≥19 kg\u002Fm2\n\nExclusion Criteria:\n\n1. Patients with malnutrition and\u002F or BMI \\\u003C19\n2. Patients with active eating disorders (as identified by history of pre-enrollment nutrition screen)\n3. Diabetes mellitus requiring medication management (both insulin and non-insulin requiring). Patients with diabetes mellitus controlled by diet alone (i.e. patients not requiring anti-glycemic medications) are NOT excluded and are eligible for participation.\n4. Allergy to component of fasting mimicking diet (FMD)\n5. Patients with recurrent ovarian, fallopian tube and primary peritoneal carcinomas with relapse within 6 months of completion of last platinum-based chemotherapy regimen (i.e. patients with platinum-resistant disease)",{"count":462,"type":23},170,[26],"Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed.\n\nShort term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group.\n\nThis trial tests whether platinum-taxane chemotherapy combined with a FMD in advanced and recurrent ovarian, fallopian tube and primary peritoneal cancer patients is associated with decreased toxicity and\u002F or improved tumor response to therapy.",[466,467],"Ovarian Cancer","Chemotherapeutic Toxicity","2024-05-05",{"date":470,"type":34},"2024-05-07",{"date":472,"type":23},"2024-05-25",{"date":474,"type":23},"2031-06-01",{"name":40,"class":41},{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":24,"phases":486,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":42},"100323500","phase-2-intra-articular-platelet-rich-plasma-compared-with-viscosupplementation-in-the-treatment-of-knee-osteoarthritis-100323500","NCT03491761","Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis","Does Intra-articular Platelet-Rich Plasma Injection Provide Superior Outcomes Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis?","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Chronic pain (\\>3 months)\n* Grade 2 -3 according to Kellgren- Lawrence (K-L) classification system (using bilateral anteroposterior radiograph image acquired while the patient is weight-bearing with both knees in full extension)\n* Minimum score of 40 out of possible 100 on the VAS (Visual Analog Scale) for pain\n* Age 18 to 75 years old\n* Physical exam and medical history\n* Complete Blood Count to include platelets and differential (CBC with Diff) within normal limits\n* C-Reactive Protein (CRP) within normal limits\n* Sed Rate (ESR) within normal limits\n* Survey of current medications\n\nExclusion Criteria:\n\n* Presence of major axial deformity (\\>5° valgus or varus deviation)\n* Surgery on target knee within 12 months prior to scheduled treatment\n* Autoimmune disorder\n* Active infections\n* Immuno-suppression (e.g., AIDS, etc.)\n* Anti-coagulant therapy\n* Use of NSAIDs 5 days prior to blood draw or up to 7 days after last PRP \u002F HA treatment\n* Hemoglobin (Hg) \\\u003C12 g\u002FdL\n* Platelet counts (PLT) \\\u003C150,000 \u002Fmm3\n* Previous infiltrative treatment within 3 weeks prior to scheduled treatment\n* Pregnancy\u002FBreastfeeding\n* Hypersensitivity to HA\n* Inability to complete an MRI due to metal implants or claustrophobia\n* Diabetes\n* Active treatment for a malignancy\n* Active wound in the knee\n* Recent history of knee trauma\n* Vasovagal history\n* An injection of hyaluronic acid (HA) or platelet-rich plasma (PRP) to the affected knee within the last two years.\n* In the judgment of the investigator, the patient is unable to perform and\u002For complete all of the study visits or treatments required.","75 Years",{"count":485,"type":23},100,[56],"This is a single-center, prospective, randomized, single-blind, comparator therapy, parallel group study for symptomatic patients diagnosed with knee osteoarthritis. The aim is to demonstrate superior efficacy of platelet-rich plasma (PRP) as compared to hyaluronic acid (HA) in treating knee osteoarthritis. This aim will be objectively measured by endpoint consisting of changes in cartilage thickness from baseline in the MRI. The Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire will be used to calculate The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score. It will measure changes in pain and function from baseline. Approximately 100 subjects will be treated at NorthShore University HealthSystem (NorthShore) as part of this study. This study has the potential to improve outcomes in a very common chronic degenerative disease, osteoarthritis, which can have a significant effect on individuals' quality of life.",[489],"Knee Osteoarthritis",[491,492,489,493,494,495,496],"Platelet Rich Plasma (PRP)","Viscosupplementation","Hyaluronic Acid (HA)","WOMAC","KOOS","Euflexxa","2024-02-23",{"date":499,"type":34},"2024-02-28",{"date":501,"type":34},"2018-06-13",{"date":229,"type":23},{"name":40,"class":41},{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":512,"studyType":127,"phases":4,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":42},"100406893","long-term-outcomes-following-hernia-repair-with-mesh-100406893","NCT04578340","Long Term Outcomes Following Hernia Repair With Mesh","Inclusion Criteria:\n\n* abdominal hernia repair using mesh\n\nExclusion Criteria:\n\n* less than 18 years old",{"count":511,"type":23},4700,"5 Years","The objective of this study is to establish the extent to which mesh improves quality of life and surgical outcomes following hernia repair.",[515],"Abdominal Hernia","2023-11-11",{"date":518,"type":34},"2023-11-14",{"date":520,"type":34},"2020-10-01",{"date":522,"type":23},"2026-10-01",{"name":40,"class":41},{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":42},"100487402","phase-4-efficacy-of-azelastine-and-mometasone-irrigation-in-comparison-to-nasal-sprays-in-patients-with-chronic-rhinitis-100487402","NCT05626621","Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis","Inclusion Criteria:\n\n* Adults 18 years and older seeking treatment for chronic rhinitis and willing to undergo six months of topical therapy.\n* Diagnosis of Chronic Rhinitis.\n\nExclusion Criteria:\n\n* The patient has diagnosis(es) other than chronic rhinitis that can account for his\u002Fher symptoms (septal deviation, nasal valve collapse, chronic sinusitis).\n* Use of oral antihistamines or oral steroids, unless patient undergoes a 4 week washout period.\n* Smokers (tobacco, marijuana, vaping, etc.).\n* Known or suspected pregnancy, or lactation.\n* Other medical conditions that the investigator believed would confound the study.\n* Allergy to study drugs.",{"count":531,"type":23},81,[82],"The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is:\n\nDo high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastine combined with nasal steroid mometasone as compared to the standard low pressure, low volume delivery mechanisms in nasal sprays?\n\nSubjects will complete six months of one of three medication regimens:\n\n1. Saline irrigation followed by azelastine spray and mometasone spray\n2. Mometasone saline irrigation\n3. Azelastine saline irrigation combined with mometasone saline irrigation.",[535],"Chronic Rhinitis",[537,538,539,540,541,542],"mometasone","azelastine","irrigation","topical therapy","nasal spray","chronic rhinitis","2023-07-25",{"date":545,"type":34},"2023-07-28",{"date":547,"type":34},"2022-11-23",{"date":549,"type":23},"2026-08",{"name":40,"class":41},{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":42},"100298739","phase-4-methadone-and-quality-of-postoperative-recovery-100298739","NCT03168958","Methadone and Quality of Postoperative Recovery","Inclusion Criteria:\n\n* All patients presenting for elective cardiac surgery with CPB will be eligible for enrollment\n\nExclusion Criteria:\n\n* Preoperative renal failure requiring dialysis or severe renal dysfunction (serum creatinine \\> 2.0 mg\u002FdL)\n* Significant hepatic dysfunction (liver function tests \\> 2 times upper normal limit)\n* Pulmonary disease necessitating home oxygen therapy\n* Preoperative requirement for inotropic agents or intraaortic balloon pump to maintain hemodynamic stability\n* Allergy to methadone or fentanyl\n* Significant preoperative pain requiring treatment with opioids or recent history of opioid abuse\n* Inability to speak or read the English language or neurologic conditions that may impair the ability to complete the QoR 40 questionnaire.",{"count":558,"type":23},130,[82],"Patients undergoing cardiac surgery often experience moderate to severe pain in the early postoperative period. A number of methods have been used to help control pain after surgery; however, each of these techniques adds additional costs and risks. A simple and effective way to decrease this pain is to administer a long-acting opioid in the operating room. Methadone is a opioid that can produce analgesia (pain relief) that lasts up to 48 hours when given in large doses (0.3 to 0.4 mg\u002Fkg). Previous studies have demonstrated that both pain and requirements for analgesic medications are significantly reduced for up to three days after surgery if methadone is given at induction (the start) of anesthesia. In the study that was performed at Evanston Hospital, cardiac surgical patients who were given methadone also appeared to \"feel better\" after surgery compared to those given a standard or typical intraoperative opioid. The aim of this randomized clinical trial is to determine whether overall quality of postoperative recovery can be enhanced if methadone is given in the operating room. Quality of recovery will be determined by using a validated scoring system, the QoR 40, which will be given to patients to complete on the first three days after surgery.",[562],"Quality of Recovery Scores","2020-08-21",{"date":565,"type":34},"2020-08-24",{"date":567,"type":34},"2018-12-25",{"date":569,"type":23},"2021-07-25",{"name":40,"class":41},{"id":572,"slug":573,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":439,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":42},"100354348","phase-4-effect-of-methadone-and-hydromorphone-on-the-qt-interval-after-anesthesia-and-surgery-100354348","NCT03893734","Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery","Inclusion Criteria:\n\n* All patients presenting for elective surgical cases requiring general anesthesia and associated with moderate-to-severe postoperative pain will be eligible for enrollment.\n\nExclusion Criteria:\n\n* History of arrhythmias, pacemaker, or defibrillator\n* Allergy to methadone or hydromorphone\n* Preoperative altered mental status\n* Abnormal serum electrolyte values\n* Existence of significant valvular disease or cardiac rhythm other than sinus\n* Significant preoperative pain requiring treatment with opioids or recent history of opioid abuse",{"count":578,"type":23},140,[82],"A number of drugs used in the perioperative period may cause prolongation of the QT interval on the electrocardiogram (EKG). These drugs include inhalational agents, antiemetic agents, pain medications, and drugs used to reverse the effects of muscle relaxants. Approximately 80% of patients undergoing a general anesthetic will demonstrate significant prolongation of the QT interval on the EKG in the postanesthesia care unit (PACU) following surgery. The concern with QT interval prolongation is that it can result in a potentially lethal ventricular arrhythmia termed torsade des pointes. Despite the concurrent use of several of these medications in a typical general anesthetic, torsade des pointes is a rare event in the perioperative period. In the past decade, the use of intravenous methadone as part of a balanced anesthetic technique has increased significantly. A single dose provided at induction of anesthesia can provide prolonged (24-48 hours) relief from pain. Studies in patients receiving long-term treatment with methadone for addiction therapy or chronic pain have revealed that these patients are at risk for QT prolongation, torsade des pointe, and cardiac death. However, the effect of a single intravenous dose of methadone used in the operating room on the QT interval is uncertain. The aim of this randomized clinical trial is to compare the impact of methadone, when compared to the more commonly-used opioid hydromorphone, on QT prolongation measured with a 12-lead EKG in the PACU and on postoperative day 1. We hypothesize that methadone will not result in significant QT prolongation when used as part of a standardized general anesthetic.",[582],"EKG-QT Prolongation","2019-09-11",{"date":585,"type":34},"2019-09-13",{"date":587,"type":34},"2018-05-01",{"date":589,"type":23},"2020-12-23",{"name":40,"class":41},""]